Keywords: Gilead Sciences, Yale School of Medicine, Cancer drug research
Gilead Sciences in $100 million cancer research collaboration with Yale
Article | 31 March 2011
California, USA-based Gilead Sciences (Nasdaq: GILD) has entered into a multi-year research collaboration with Yale School of Medicine focused on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
